Skip to content

Pharma Leaders Push for SME Relief in High-Stakes Chancellery Dialogue

Germany’s pharma SMEs are drowning in red tape—12x more than other sectors. Can a Chancellery dialogue turn the tide for these vital drug suppliers?

There is a pharmacy store and there is a vehicle in front of it and there is a building in the left...
There is a pharmacy store and there is a vehicle in front of it and there is a building in the left corner.

Pharma Leaders Push for SME Relief in High-Stakes Chancellery Dialogue

Pohl-Boskamp, a leading pharmaceutical company, sent its CEO Marianne Boskamp and Managing Director Babette Reiken to a dialogue at the Chancellery. They were invited by Chancellery Minister Thorsten Frei (CDU). The event, known as the Pharmaceutical Dialogue, aimed to address crucial issues in the pharmaceutical sector.

Boskamp, during the dialogue, pinpointed two key areas for improvement. Firstly, she emphasised the need for adjusted framework conditions to help small and medium-sized enterprises (SMEs) maintain competitiveness. Secondly, she proposed an acceleration initiative to tackle the complex and fragmented regulatory maze that often hinders progress.

Boskamp underscored the significant burden faced by pharmaceutical SMEs. She noted that they bear twelve times the bureaucratic load compared to other industries. This heavy burden, she stressed, threatens the viability and growth of these sme companies.

The Pharmaceutical Dialogue at the Chancellery saw Pohl-Boskamp at the forefront, advocating for measures to bolster Germany's position as a healthcare hub. Boskamp highlighted the critical role of SMEs in the pharmaceutical sector, with 85% of companies being SMEs. These companies supply around 80% of essential medications but receive only 7% of health insurers' drug expenditures.

The Pharmaceutical Dialogue at the Chancellery, attended by Pohl-Boskamp, underscored the need for supportive framework conditions and regulatory acceleration to sustain Germany's pharmaceutical sme companies. These companies, despite their significant contributions, face disproportionate bureaucratic burdens. The dialogue marks a step towards addressing these challenges and strengthening Germany's healthcare sector.

Read also:

Latest